A resolution expressing support for the designation of June 19, 2025, as "World Sickle Cell Awareness Day" in order to increase public awareness across the United States and global community about sickle cell disease and the continued need for empirical research, early detection screenings, novel effective treatments leading to a cure, and preventative care programs with respect to complications from sickle cell anemia and conditions relating to sickle cell disease.
- Bill Number
- S.Res. 292
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-06-18: Referred to the Committee on Foreign Relations. (text: CR S3476)
- Last Updated
- 2026-07-08T15:17:31Z
AI-Generated Summary
Purpose
This Senate resolution (S. Res. 292) expresses support for designating June 19, 2025, as "World Sickle Cell Awareness Day." Its main goal is to raise public awareness in the United States and globally about sickle cell disease (SCD), a genetic blood disorder. It highlights the need for more research, early screening tests for newborns, new treatments that could lead to a cure, and programs to prevent complications like pain crises, strokes, and organ damage.
Key Provisions
The resolution includes a detailed preamble with background facts on SCD and sickle cell trait (SCT, a milder gene variation that can be passed to children). It then outlines seven specific actions for the Senate:
- Support for awareness day: Endorses the goals and ideals of World Sickle Cell Awareness Day, themed "Global Action, Local Impact: Empowering Communities for Effective Self-Advocacy."
- Equity in access: Commits to promoting fair access to SCD treatments across all economic, racial, and ethnic groups to improve health outcomes.
- Global and domestic policy: Calls on the Department of Health and Human Services (HHS) to develop worldwide policies supporting SCD efforts, including newborn screenings, treatments, and services in partnership with local governments.
- Removing barriers: Supports eliminating obstacles to innovative therapies (like cell, gene, and gene-editing treatments) in Medicare and Medicaid programs for vulnerable patients.
- Public engagement: Encourages communities in the U.S. and worldwide to organize events, programs, and activities on June 19, 2025, to educate about SCD, SCT, prevention, treatments, and support services.
- Interagency coordination: Urges the President to create a Sickle Cell Disease Interagency Group involving HHS, the Department of Veterans Affairs, National Institutes of Health (NIH), Food and Drug Administration (FDA), and Centers for Medicare & Medicaid Services (CMS) to advance policies for equitable access to new SCD therapies.
- Addressing bias: Directs the interagency group to tackle biases in U.S. and global healthcare systems that disproportionately affect SCD patients, while considering future curative treatments.
Significant Changes to Existing Law
This is a non-binding resolution, so it does not amend or create new laws. It builds on past efforts, such as the 1972 National Sickle Cell Anemia Control Act (which authorized education, screening, and research programs) and 2020 recommendations from the National Academies for better therapies and access. Instead, it reinforces and expands calls for action without legal enforcement.
Potential Impacts
- On government agencies: Could prompt HHS, NIH, FDA, and CMS to prioritize SCD in budgets, policies, and collaborations, potentially leading to more funding for research and global partnerships (e.g., with the World Health Organization). It may encourage interagency efforts to reduce healthcare disparities.
- On citizens: Raises awareness to help families with SCD or SCT seek early diagnosis and care, potentially improving quality of life and reducing mortality (e.g., through better newborn screenings). It targets underserved groups, like African-American and Hispanic-American communities, where SCD is more common.
- On international relations: Promotes U.S. leadership in global SCD initiatives, supporting resolutions from the World Health Assembly and aiding resource-poor countries (e.g., in sub-Saharan Africa) where child mortality from SCD is high. This could foster health diplomacy and joint programs.
Main Stakeholders Affected
- Individuals and families with SCD or SCT: About 100,000 people with SCD and up to 3 million with SCT in the U.S., plus millions worldwide, especially those of African, Hispanic, Mediterranean, or South Asian descent.
- Communities and advocacy groups: Organizations like the Sickle Cell Disease Association of America and global networks, benefiting from increased visibility and self-advocacy.
- Healthcare providers and researchers: Doctors, hospitals, and scientists who could gain support for screenings, treatments (e.g., stem cell transplants or new gene therapies approved in 2023), and preventive care.
- Government and policymakers: Federal agencies (HHS, NIH, FDA, CMS) and local governments involved in health programs; veterans with SCD through the Department of Veterans Affairs.
- Global populations: Children and families in high-prevalence regions like Africa, where daily births of SCD-affected infants are high and survival rates are low without intervention.
Notable Legal, Constitutional, or Political Implications
- Legal: As a simple resolution, it has no binding force but signals congressional intent, potentially influencing future appropriations or executive actions under existing health laws like the Affordable Care Act for equitable access.
- Constitutional: Aligns with Congress's role in promoting general welfare (Article I, Section 8) by addressing public health without infringing on states' rights or individual liberties.
- Political: Highlights health equity and racial disparities in healthcare (SCD primarily affects Black communities), potentially building bipartisan support for SCD funding amid broader debates on medical innovation and global health. It honors historical figures like Dr. Kwaku Ohene-Frempong and past legislation, reinforcing U.S. commitment to underrepresented health issues without partisan controversy.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (2)
Sen. Van Hollen, Chris [D-MD], Sen. Alsobrooks, Angela D. [D-MD]
Recent Actions
- 2025-06-18: Referred to the Committee on Foreign Relations. (text: CR S3476)
- 2025-06-18: Introduced in Senate
Bill Versions
- Expressing support for the designation of June 19, 2025, as World Sickle Cell Awareness Day in order to increase public awareness across the United States and global community about sickle cell disease and the continued need for empirical research, early detection screenings, novel effective treatments leading to a cure, and preventative care programs with respect to complications from sickle cell anemia and conditions relating to sickle cell disease. — issued 2025-06-18 — PDF (7 pages)